Gonadotropin-Releasing Hormone (GnRH) Agonists and Antagonists

This policy covers gonadotropin‑releasing hormone (GnRH) agonists and antagonists for FDA‑approved indications and select off‑label uses supported by compendia or medical literature, including use in controlled ovarian stimulation, suppression of estrogen/testosterone for oncology or reproductive conditions, and standard fertility preservation for patients (e.g., those with cancer) whose medically necessary treatment may cause iatrogenic infertility. Coverage is limited to therapies consistent with FDA labeling or nationally recognized authoritative sources (off‑label uses require supporting peer‑reviewed evidence), constrained to standard ASCO/ASRM‑defined fertility preservation procedures, and subject to the member’s benefit plan terms and applicable state regulations (with certain state‑specific mandates such as Ohio).

"For HCSC members residing in Ohio, coverage is required for any FDA-approved drug when prescribed for a use recognized as safe and effective in one or more standard medical reference compendia."